Literature DB >> 16614689

The cost of marginal medicine is too high.

Ezekiel J Emanuel.   

Abstract

Mesh：

Year:  2005        PMID： 16614689      PMCID： PMC1681708     

Source DB:  PubMed          Journal:  MedGenMed        ISSN： 1531-0132


× No keyword cloud information.
  5 in total

1.  The price tag on progress--chemotherapy for colorectal cancer.

Authors:  Deborah Schrag
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

Review 2.  High and rising health care costs. Part 3: the role of health care providers.

Authors:  Thomas Bodenheimer
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

3.  Health care expenditures reexamined.

Authors:  Victor R Fuchs
Journal:  Ann Intern Med       Date:  2005-07-05       Impact factor: 25.391

4.  Shattuck Lecture--cutting cost without cutting the quality of care.

Authors:  A C Enthoven
Journal:  N Engl J Med       Date:  1978-06-01       Impact factor: 91.245

5.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245
  5 in total
  1 in total

1.  Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?

Authors:  Nicole Grössmann; Claudia Wild
Journal:  ESMO Open       Date:  2017-01-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.